Location of Repository

TRAIL shows potential cardioprotective activity.

By Toffoli B, Bernardi S, Candido R, Zacchigna S, Fabris B and Secchiero P.


Recent clinical trials carried out in patients with advanced cancer have shown that recombinant TRAIL administration is usually safe and well tolerated when used either alone or in association with chemotherapeutic drugs. Notably, anticancer chemotherapy can be associated to cardiomiopathy. We have here demonstrated that TRAIL (administrated as either recombinant soluble TRAIL or as AAV-TRAIL expression viral vector) reduced the development of cardiomyopathy in the ApoE(-/-) diabetic mouse model. These data suggest, for the first time, that therapeutically administration of TRAIL might have a cardioprotective effect

Topics: TRAIL, ApoE-/- diabetic mouse, cardiomiopathy
Year: 2012
DOI identifier: 10.1007/s10637-010-9627-8
OAI identifier: oai:iris.unife.it:11392/1506913
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/11392/15... (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.